Black Rock Inc. Chemo Centryx, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $4.6 Million - $10.7 Million	207,299 Added 4.47%	4,844,951 $250 Million
Q2 2022 Aug 12, 2022	BUY	$15.36 - $27.51 $5.27 Million - $9.44 Million	343,317 Added 7.99%	4,637,652 $115 Million
Q1 2022 May 12, 2022	SELL	$22.22 - $39.12 $714,417 - $1.26 Million	-32,152 Reduced 0.74%	4,294,335 $108 Million
Q4 2021 Feb 10, 2022	SELL	$18.38 - $40.5 $1.88 Million - $4.13 Million	-102,067 Reduced 2.3%	4,326,487 $158 Million
Q3 2021 Nov 09, 2021	SELL	$13.18 - $19.83 $3.04 Million - $4.58 Million	-230,843 Reduced 4.95%	4,428,554 $75.7 Million
Q2 2021 Aug 11, 2021	BUY	$9.59 - $50.88 $44.7 Million - $237 Million	4,659,397 New	4,659,397 $62.4 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.